The combination of anti-EGFRs and doublet chemotherapy is considered the optimal upfront option for patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC). The prophylactic or reactive treatment with tetracyclines for EGFR inhibitor-induced skin toxicity is currently clinical practice, though non-conclusive results are available.
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study / Raimondi, A., Corallo, S., Lonardi, S., Antoniotti, C., Rimassa, L., Amatu, A., Tampellini, M., Racca, P., Murialdo, R., Clavarezza, M., Zaniboni, A., Toscano, G., Tomasello, G., Petrelli, F., Antonuzzo, L., Giordano, M., Cinieri, S., Longarini, R., Niger, M., Antista, M., et al.. - In: SUPPORTIVE CARE IN CANCER. - ISSN 1433-7339. - STAMPA. - 29:(2021), pp. 3971-3980. [10.1007/s00520-020-05972-2]
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study
Antonuzzo, Lorenzo;
2021
Abstract
The combination of anti-EGFRs and doublet chemotherapy is considered the optimal upfront option for patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC). The prophylactic or reactive treatment with tetracyclines for EGFR inhibitor-induced skin toxicity is currently clinical practice, though non-conclusive results are available.
| File | Dimensione | Formato | |
|---|---|---|---|
|
s00520-020-05972-2.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
359.11 kB
Formato
Adobe PDF
|
359.11 kB | Adobe PDF | Richiedi una copia all'autore |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
